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A B S T R A C T
Prostate cancer is one of the most common cancers affecting men. Bone scan is part of the staging modality
commonly used to evaluate bone metastasis. A bone scan with diffused increased skeletal tracer uptake relative
to soft tissue, combined with faint renal activity is known as a superscan. However, a primary concern are false
negatives associated with bone scans, where diffuse metastasis is indistinguishable on superscans. In this study,
we performed xSPECT/CT Bone and standard OSEM SPECT/CT reconstruction algorithm in ten prostate cancer
patients with high PSA levels, where they initially seem relatively unremarkable on planar images. All patients
with extensive bone metastases showed either relatively unremarkable scans or did not demonstrate the true
extent of metastatic burden as seen on planar images. Uptake was further confirmed by the correlative diffuse
bone lesions on CT images. Our reports also indicated that xSPECT/CT reconstructed images were far superior in
delineating focal areas of osteoblastic bone metastasis, when compared with whole body planar images or
SPECT/CT images. The extent of metastatic evidence is delineated with excellent clarification by xSPECT/CT
images. We propose that whole body xSPECT/CT image reconstruction, or at least SPECT/CT, should be per-
formed in patients with high PSA levels, along with planar imaging, to improve diagnostic accuracy of bone
scans in prostate cancer staging.
1. Introduction
Prostate cancer is one of the most common cancers affecting men
worldwide in 2019 (Siegel et al., 2019). Post-mortem autopsies have
demonstrated that skeletal system tends to be the most frequent site for
metastases (approximately 80%) (Imbriaco et al., 1998; Shen et al.,
2014). Widespread skeletal metastasis is synonymous with high mor-
bidity and poor prognosis; often accompanied with severe complica-
tions such as impaired mobility, pathological fractures, spinal cord
compressions and generalised skeletal pain (Keller and Brown, 2004).
The metastatic extent of prostate cancer with bone involvement cor-
relates with poorer prognosis and reduced survival rate (Soloway et al.,
1988; Sabbatini et al., 1999; Halabi et al., 2003). For early diagnosis of
prostate cancer, routine clinical and imaging tools includes diagnostic
tests such as serum Prostate-Specific Antigen (PSA) levels, transrectal
ultrasound (TRUS), computed tomography (CT) and magnetic re-
sonance imaging (MRI); whereby the invasive nature of TRUS-guided
core needle biopsy is the gold standard (De Visschere et al., 2010).
Therefore, a non-invasive method for early detection and accurate
staging is vital to stop progression to widespread skeletal metastatic
disease.
Skeletal scintigraphy, also known as radionuclide bone scan, is a
common nuclear medicine imaging modality used to detect skeletal
metastases in prostate cancer patients (Pollen et al., 1984; Knudson
et al., 1991; Gnanasegaran et al., 2009; Tabotta et al., 2019). With the
ability to examine the entire skeleton, bone scan is one of the most
frequently performed radionuclide imaging examinations due to its
high sensitivity (Love et al., 2003; Tabotta et al., 2019). Therefore, it
has better diagnostic value compared to standard-of-care imaging, such
as plain radiographs or CT, in detecting early or asymptomatic bone
metastasis (Love et al., 2003; Shen et al., 2014; Manohar et al., 2017).
This procedure requires a “bone-seeking” agent that allows us to vi-
sualise new bone formation or any unusual rate of bone turnover by
binding to osteoblasts (Agrawal et al., 2015; Imbriaco et al., 1998),
using Technetium99m-methyldiphosphonate (Tc99m-MDP). Images are
typically acquired at approximately 3 h after intravenous injection. This
delay between time-of-injection and image acquisition allows for ex-
cessive radioisotope clearance from soft tissues and renal system,
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resulting in improved skeletal system visual clarity (Love et al., 2003).
Gamma cameras are typically used to obtain planar images for bone
scans, but the modern hybrid technology of Single-Photon Emission
Computed Tomography (SPECT)/CT allows for faster image acquisition
with higher accuracy. In today's modern healthcare system, bone scans
are relatively quick, inexpensive and widely available.
A “superscan” is defined as bone scan planar imaging with diffuse
increased skeletal tracer uptake relative to soft tissue, combined with
diminished or non-existent renal activity (Brenner et al., 2012; Love
et al., 2003). It has added diagnostic ability to detect early bone lesion
changes anywhere with high sensitivity (more than 80%) (Manohar
et al., 2017). However, a major drawback of superscans are the false
negatives associated with bone scans demonstrating diffuse metastases,
whereby these scintigraphs are almost indistinguishable on planar
images (Agrawal et al., 2015; Al-Tamimi et al., 2012). In addition, su-
perscans may produce inconclusive results and false interpretations due
to metabolic bone diseases (Brenner et al., 2012).
This study aims to evaluate the accuracy of a superscan as defined
above, with combination of 3D SPECT/CT reconstructed images for
detecting and diagnosing bone metastases in prostate cancer patients.
Additionally, this study also looks into optimising and enhancing the
current skeletal scintigraphy protocols for patients at Sunway Medical
Centre, Malaysia.
2. Methodology
Ten prostate cancer patients presented with markedly elevated
serum PSA levels were included in this study. All patients first under-
went routine planar imaging, which was acquired 3 h after an injection
of Tc99m-MDP, with a dose of 740 MBq. Subsequently, a hybrid
SPECT/CT imaging was performed, consisting of whole-body (vertex-
of-skull to pelvis) 3D SPECT study, immediately followed by a low-dose
CT scan.
All SPECT/CT hybrid images were reconstructed using iterative
xSPECT Bone algorithm (developed by Siemens Healthcare) and stan-
dard Ordered-Subset Expectation-Maximisation (OSEM) SPECT re-
construction algorithm for visual clarity comparison. Both standard
OSEM SPECT and Siemens’ xSPECT Bone reconstructions were in-
dividually fused with CT images for anatomical localisation and at-
tenuation correction. Examination protocols and reconstruction algo-
rithm parameters are listed below in Table 1. Four of the patients
discussed below were representative of the ten cases.
3. Results
All patients with extensive bone metastases showed either relatively
unremarkable tracer uptake or did not demonstrate the true extent of
metastatic burden as seen on planar images (Fig. 1). As shown in Fig. 1,
patients 1 and 3 demonstrate relatively unremarkable tracer uptake in
both anterior and posterior images, with patients 2 and 4 indicating
possible but inconclusive focal tracer uptake.
Both OSEM SPECT and xSPECT Bone reconstructions demonstrate
widespread osteoblastic metastases, where xSPECT Bone reconstruction
algorithm reveals sharper delineation of vertebral bodies, intervertebral
disc spaces and spinous processes (Fig. 2). xSPECT Bone reconstructed
images show diffusely intense skeletal uptake with higher visual clarity
when compared with the standard OSEM SPECT reconstructed image.
Focal tracer uptake shows improved delineation and could be appre-
ciated with higher contrast and resolution on xSPECT/CT fused images
(Figs. 3 and 4). Fig. 3 confirmed generalised sclerosis with few focal
uptake areas seen in the pelvis, correlated with high resolution on
xSPECT/CT images, providing accurate diagnosis. Accurate delineation
of sclerotic vertebral lesions (Fig. 4) are shown with high contrast and
resolution in xSPECT/CT fused images.
Tracer uptake was confirmed on all hybrid scans with correlation of
diffuse bone lesions on CT images and increased tracer uptake on re-
constructed OSEM SPECT and xSPECT Bone images. xSPECT/CT images
sharply define extensive osteoblastic metastases along with improved
clarity of all long bones, skull, ribs and pelvis, demonstrating significant
diagnostic value when compared with planar images and OSEM SPECT/
CT (Figs. 2 and 4). In addition, xSPECT/CT reconstructed images were
far more superior than OSEM SPECT/CT in showing focal uptake of
small osteoblastic lesions (Fig. 3). In patient 1, xSPECT/CT showed
focal uptake in the small sclerotic lesion at sacrum, which was negative
on SPECT/CT (Fig. 3). Hence, OSEM SPECT/CT may potentially lead to
false negative results. Furthermore, skeletal metastases, active degen-
erative changes and physiological skeletal tracer uptake is well defined
and differentiated in xSPECT/CT.
Table 1
Examination and reconstruction protocol.
Scanner Siemens Symbia Intevo 16
Tc99m-MDP injected dose 740 MBq
Scan delay 3 h post-injection
Scan parameters 2D Planar: 12 cm/min; 256 × 1024 matrix
3D SPECT: 60 views @ 7 secs/view; 256 × 256
matrix
CT: 110 kV; 75 ref. mAs; 5 mm slice thickness
Reconstruction algorithm
parameters
OSEM SPECT/CT: 8 iterations; 4 subsets; 12 mm
Gaussian filter xSPECT/CT Bone: 20 iterations; 1
subset; 20 mm Gaussian filter
Fig. 1. Planar bone scans visually evaluated as superscans. Patients 1–3 show relatively unremarkable appearances on both anterior and posterior views. Patient 1
could be considered as inconclusive metastatic evidence. Increased focal tracer uptake in patients 2 and 3 could be interpreted as osteo-degenerative disease. In
patient 4, tracer uptake in the humerus could be metastatic evidence, whereas lumbar and pelvic regions demonstrate inconclusive focal tracer uptake.
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4. Discussion & conclusion
Prostate cancer is the most common condition frequently associated
with a superscan (Soloway et al., 1988). A study of 307 prostate cancer
patients reported that 15% demonstrated superscan appearances, of
which 72% of the same group (15%) had serum PSA levels of 178 ng/ml
and 122 ng/ml in symptomatic and asymptomatic patients respectively
(Manohar et al., 2017). However, the limitation of superscans is that it
is unable to distinguish between metabolic bone disorders from skeletal
malignancy (Agrawal et al., 2015; Gnanasegaran et al., 2009). Our
study also demonstrated that superscans also provide inconclusive
skeletal metastases and the inability to delineate the true extent of
metastatic disease or small lesions (Fig. 1), thereby affecting patient
management.
The xSPECT Bone reconstructed images demonstrated higher con-
trast and increased resolution between bone and background tracer
uptake, resulting in superior diagnostic accuracy. The extent of meta-
static evidence is clearly delineated with increased clarity by xSPECT
Bone. Skeletal metastases in patient 2 may be demonstrated in planar
images (Fig. 1), but the true extent of metastatic disease and intensity of
tracer uptake is delineated with higher visual clarity and evaluation on
xSPECT Bone reconstructions, further confirmed by corresponding
Fig. 2. Patient 1: Comparison of planar bone scan (A, B), OSEM SPECT (C–E) and xSPECT Bone (F–H) reconstruction algorithms. xSPECT Bone demonstrates higher
contrast and resolution within metastatic lesions, as well as clear delineation of ribs and pelvis.
Fig. 3. In this SPECT/CT study of patient 1, comparison of axial slice through middle of pelvis between OSEM SPECT and xSPECT Bone reconstruction shows
improved clarity of sacro-iliac joints and sacral foramina. xSPECT Bone reconstruction (E, F) sharply delineates a small but intense focal tracer uptake seen at the
right sacral ala (arrow), compared to OSEM SPECT (B, C); corresponding with sclerotic lesion seen on CT (A, D).
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sclerotic lesions seen on CT (Fig. 4).
When compared with standard OSEM SPECT images, xSPECT Bone
reconstructed images were far superior in delineating focal areas of
osteoblastic metastases (Fig. 2) and improved visualisation of the entire
skeletal system, prior to fusing with CT images. The xSPECT Bone
images also provided far more diagnostic information when compared
with planar images. The superiority of image contrast and resolution in
xSPECT Bone provides the ability to resolve any discrepancies that may
arise when defining disease progression from metastatic evaluation or
non-oncological bone diseases, such as bone remodelling from trauma,
physiological tracer uptake or osteo-degenerative changes, even with
small lesions (Delcroix et al., 2018; Duncan and Ingold, 2018). This
advancement in bone scans could offer clinicians with comprehensive
understanding of the true skeletal metastatic burden involved in pros-
tate cancer, especially in detecting tiny skeletal pathologies before
progressing to extensive metastasis, as shown in Fig. 3.
Here, we propose that a whole-body (vertex-of-skull to pelvis)
xSPECT/CT image reconstruction should be performed in patients with
elevated serum PSA levels, along with standard planar imaging. In
places that do not have such services, a standard OSEM SPECT image
reconstruction should suffice. If patients are in critical pain and unable
to endure an extended procedure, a minimum 3D SPECT/CT study
should be performed at the region of interest instead of whole-body
imaging. If hybrid imaging is not available, a referral to the nearest
nuclear medicine department with SPECT/CT modality is advised. This
should be performed in order to enhance the diagnostic accuracy of
bone scan in staging prostate cancer as disease management, patient
outcome and quality of life relies heavily on accurate diagnosis.
To prevent inaccurate staging of other metastatic diseases, this
should not only be limited to prostate cancer, as skeletal metastases are
evident in other cancers such as breast and lung cancers (Love et al.,
2003; Shen et al., 2014; Tabotta et al., 2019). Therefore, by including
patient history and key clinical presentation and complaints, the future
use of bone scan could drastically improve diagnosis, patient outcome
and quality of life by the implementation of hybrid xSPECT/CT ima-
ging.
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